Skip to content
type1.science

GNTI-122 engineered Tregs (POLARIS)

GentiBio

Promising idea, first-in-human, and open only to a rare genotype.

What it is

A one-time autologous engineered regulatory T-cell therapy made from a person's own blood cells, designed to restore immune tolerance to the cells that make insulin in recent-onset T1D. Phase 1 POLARIS is recruiting a small, genotype-restricted group (HLA-DRB1*04:01-positive adults); no efficacy data yet.

Editorial review: .

Most recent recorded citation date: 2026-03-18. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Years awayEarly evidenceimmunotherapytregengineered-tregcell-therapynew-onsetc-peptideOfficial site ↗

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
Benefit or performance
Beta-cell preservation: The goal is beta-cell protection, and POLARIS measures biomarkers including C-peptide, but no human efficacy data are posted yet.[2]
Important harms and treatment burden
Safety: This is first-in-human autologous cell therapy in T1D; safety and tolerability are the primary endpoints, so risk is deliberately scored conservatively.[2]
Approval and country access
Phase 1 only; requires the HLA-DRB1*04:01 genotype and diagnosis within 180 daysApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Durability: Engineered Tregs are intended as a durable immune-tolerance reset, but persistence and durability in T1D remain unproven until follow-up reports. The largest POLARIS cohort (10 of 16 participants) receives GNTI-122 together with rapamycin, specifically to try to extend how long the engineered cells survive — an admission that persistence is the open question (motive and admission framing are this page's reading of the high-dose-plus-rapamycin design).[2]

Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 18 × 30 + 25 × 20 + 25 × 20 + 14 × 10 + 22 × 20 = 2120; divide by total weight 100. Unrounded weighted result: 21.2.

Beta-cell preservation18

The goal is beta-cell protection, and POLARIS measures biomarkers including C-peptide, but no human efficacy data are posted yet.[2]

Durability25

Engineered Tregs are intended as a durable immune-tolerance reset, but persistence and durability in T1D remain unproven until follow-up reports. The largest POLARIS cohort (10 of 16 participants) receives GNTI-122 together with rapamycin, specifically to try to extend how long the engineered cells survive — an admission that persistence is the open question (motive and admission framing are this page's reading of the high-dose-plus-rapamycin design).[2]

Safety25

This is first-in-human autologous cell therapy in T1D; safety and tolerability are the primary endpoints, so risk is deliberately scored conservatively.[2]

Eligibility breadth14

Extremely narrow. POLARIS enrolls just 16 adults aged 18-55, diagnosed within 180 days, at US specialist sites (per the listed locations) — and participants must be HLA-DRB1*04:01 positive, a genotype restriction that rules out most people with T1D (page's prevalence assessment). This is, on this page's assessment, a proof-of-mechanism population, not a preview of who could be treated.[2]

Maturity22

Clinical-stage, but only phase 1 and single-arm; first participant dosed in 2026, per the cited company announcement.[3]

The full picture

GNTI-122 is the most concrete engineered-Treg entry now in human testing for type 1 diabetes. The product is made from the participant's own blood cells and engineered to counter the autoimmune imbalance that destroys beta cells. POLARIS is a small phase 1, open-label study, so every score is still about plausibility and maturity rather than demonstrated disease modification. The reason it matters is strategic: if engineered Tregs can survive, traffic correctly, and preserve C-peptide without broad immune suppression, they could become the immune-protection half of a future cure stack.

The trial itself is deliberately tiny. POLARIS (NCT06919354) plans 16 adults aged 18 to 55, diagnosed within 180 days of screening, at US specialist sites (10 locations listed; country detail per the registry locations module). It runs as three sequential dose cohorts: three people get a low dose of GNTI-122, three get a high dose, and the largest group — 10 of the 16 — gets the high dose together with rapamycin, an immunosuppressant included because it may help the engineered cells survive longer (design rationale as described here; registry confirms cohort 3 is high dose plus rapamycin). It is a 78-week study, with primary completion listed as February 2028.

One caveat the headlines skip: to join POLARIS you must carry the HLA-DRB1*04:01 gene variant, because the engineered receptor is built around it. Most people with type 1 diabetes do not carry it, as understood here (not a registry figure). Whatever POLARIS shows, it will not immediately generalise to everyone with type 1 diabetes — a wider product would need receptors designed for other genotypes, which, as assessed here, is more work, not a formality.

Two honest reads on that rapamycin cohort. The optimistic one: the team is being pragmatic about a known weakness of cell therapy, and pairing the cells with a drug that buys them time is sensible engineering. The sceptical one: needing rapamycin at all cuts against the central promise of engineered Tregs, which is protection without broad immune suppression. Which read is right is exactly what the trial exists to answer, and there are no efficacy data yet either way.

Coming soon

ETA · Phase 1 POLARIS recruiting (16 participants); 78-week study, primary completion February 2028

  • →First POLARIS safety, cell-persistence and C-peptide findings (expected readouts per the registered outcomes) · Primary completion February 2028 (registry)

Sources

  1. [1]
  2. [2]
  3. [3]
  4. [4]